JS207, Junshi Biosciences’ independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class ...

Full-year 2025 net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of ...

Dr. Soon-Shiong joins Nobel laureates, former NIH directors, and leading oncology pioneers in Washington, D.C. to chart a path toward defeating cancer by 2035, with the discussion streamed live at ...

The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...

Aaron Y. Lee, MD, MSCI, explains how temporal optical coherence tomography modeling may improve longitudinal disease tracking and clinical decision-making.

A molecule that helps regulate gene activity has also been shown to drive skin cancer growth and tumors' ability to evade ...

A newly identified driver of melanoma growth not only promotes tumor blood supply but also helps tumors evade immune attack.

Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology-focused biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announces clinical data ...

Some patients with nonproliferative diabetic retinopathy had reduced vascular leakage or macular exudation after being treated orally with danegaptide, according to a study presented at Angiogenesis, ...

A molecule that helps regulate gene activity has also been shown to drive skin cancer growth and tumors' ability to evade ...